The Michael J. Fox Foundation

Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation

The grant was awarded through MJFF's Parkinson's Disease Therapeutics Pipeline Program. The program seeks to advance testing of promising therapeutic developments that address unmet medical needs in people with PD. The program is designed to fund therapeutic development with a clear focus to prevent, stop, or delay disease progression, or to reduce the challenges of daily symptoms.
Exit mobile version